Ebola virus vaccines: Where do we stand?
- 1 December 2016
- journal article
- review article
- Published by Elsevier in Clinical Immunology
- Vol. 173, 44-49
- https://doi.org/10.1016/j.clim.2016.10.016
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- A Recombinant Vesicular Stomatitis Virus Ebola VaccineNew England Journal of Medicine, 2017
- A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVANew England Journal of Medicine, 2016
- VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strainScience, 2015
- Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trialPublished by Elsevier ,2015
- Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trialPublished by Elsevier ,2015
- Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trialThe Lancet, 2014
- Ebola virus diseaseBMJ, 2014
- Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challengeNature Medicine, 2014
- Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal ruleNature Reviews Microbiology, 2009
- Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg virusesNature Medicine, 2005